Digital Therapeutics Sarcopenia Market Report 2026

Digital Therapeutics Sarcopenia Market Overview

• Digital Therapeutics Sarcopenia market size has reached to $1.54 billion in 2025 • Expected to grow to $3.21 billion in 2030 at a compound annual growth rate (CAGR) of 15.9% • Growth Driver: Rising Comorbidities Fueling The Growth Of The Market Due To Increasing Aging Population And Obesity Risk • Market Trend: Advancing Precision Therapies Through Innovative Muscle Tissue Modeling • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Digital Therapeutics Sarcopenia Market?

Digital therapeutics for sarcopenia refer to evidence-based software-driven interventions designed to prevent, manage, or treat sarcopenia, a condition characterized by progressive loss of muscle mass, strength, and function. These interventions typically leverage digital platforms to deliver personalized therapeutic strategies grounded in clinical evidence and behavioral science. The main products of digital therapeutics sarcopenia are software, devices, and services. The software component provides personalized interventions such as exercise routines and dietary plans through digital devices to help users manage muscle loss and support recovery. These solutions are distributed via channels such as online platforms, pharmacies, and others, and applications span muscle strengthening, physical activity monitoring, nutrition management, and others. They are used by various end users, including hospitals and clinics, homecare settings, rehabilitation centers, and others.

What Is The Digital Therapeutics Sarcopenia Market Growth Forecast?

The digital therapeutics sarcopenia market size is expected to see rapid growth in the next few years. It will grow to $3.21 billion in 2030 at a compound annual growth rate (CAGR) of 15.9%. The growth in the forecast period can be attributed to increasing demand for home-based chronic condition management, rising integration of ai-driven therapeutic personalization, expansion of reimbursement support for digital therapeutics, growing adoption of remote patient monitoring, increasing focus on preventive muscle health solutions. Major trends in the forecast period include increasing adoption of personalized digital therapy programs, rising use of wearable-integrated muscle monitoring, growing deployment of remote physiotherapy platforms, expansion of data-driven sarcopenia management solutions, enhanced focus on patient engagement and adherence.

What Is The Driver Of The Digital Therapeutics Sarcopenia Market?

The rising prevalence of comorbidities is expected to propel the growth of the digital therapeutics sarcopenia market going forward. Comorbidities refer to the simultaneous occurrence of two or more health conditions in the same individual. Comorbidities are rising due to the aging population, as advancing age increases the likelihood of developing multiple chronic conditions due to declining physiological function and long-term exposure to health risks. Digital therapeutics for sarcopenia are beneficial for preventing comorbidities, especially obesity, by promoting regular physical activity and muscle strengthening, which help improve metabolism and reduce fat accumulation. For instance, in March 2024, according to the World Obesity Federation, a UK-based membership organization, nearly 79% of adults affected by overweight and obesity are expected to be living in low- and middle-income nations by the year 2035, with the total number of adults with obesity projected to grow to 1.53 billion. Therefore, the rising prevalence of comorbidities is driving the growth of the digital therapeutics sarcopenia industry.

Key Players In The Global Digital Therapeutics Sarcopenia Market

Major companies operating in the digital therapeutics sarcopenia market are Sword Health Inc., Biofourmis Inc., Hinge Health Inc., Omada Health Inc., Evolv Rehabilitation Technologies Ltd., Click Therapeutics Inc., DarioHealth Corp., WellDoc Inc., Lark Technologies Inc., Kaia Health Software GmbH, Liva Healthcare A/S, Zibrio Inc., Gait Up SA, Noraxon Inc., Mira Rehab Limited, Cometa Srl., Koneksa Health Inc., Physitrack PLC, Kaia Health Inc., XRHealth USA Inc., MedRhythms Inc.

Global Digital Therapeutics Sarcopenia Market Trends and Insights

Major companies operating in the digital therapeutics sarcopenia market are focusing on developing advanced solutions, such as drug discovery platforms, to develop more targeted therapies, enhance treatment effectiveness, and accelerate the delivery of personalized care for age-related muscle loss. A drug discovery platform helps find and create new drugs faster and more effectively using advanced tools and methods. For instance, in April 2025, ProFuse Technology, an Israel-based biotechnology company, launched a new drug discovery platform focused on preventing muscle loss caused by GLP-1 weight-loss drugs, aging (sarcopenia), and cancer cachexia. Using lab-grown, highly mature muscle tissues that mimic natural muscle, the company can accurately test and screen drug candidates faster and more efficiently. This advanced platform reduces reliance on animal testing and lowers research costs. As muscle-preserving therapies gain demand, ProFuse is expanding beyond cultivated meat into biopharma, offering a breakthrough approach to address growing muscle health challenges.

What Are Latest Mergers And Acquisitions In The Digital Therapeutics Sarcopenia Market?

In August 2023, Eli Lilly and Company, a US-based pharmaceutical company, acquired Versanis Bio for $1.9 billion. This acquisition broadens Lilly's portfolio to include Versanis' principal asset, bimagrumab, which is now being tested in a Phase 2b trial alone and in combination with semaglutide in people with overweight or obesity. Versanis Bio is a US-based pharmaceutical company that specializes in developing treatments for sarcopenia.

What Defines the Digital Therapeutics Sarcopenia Market?

The digital therapeutics sarcopenia market consists of revenues earned by entities by providing services such as software-driven therapeutic interventions, integration of predictive analytics, and delivery of rehabilitation. The market value includes the value of related goods sold by the service provider or included within the service offering. The digital therapeutics sarcopenia market also includes sales of wearable devices, biosensors, and virtual and augmented reality tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Digital Therapeutics Sarcopenia Market Report 2026?

The digital therapeutics sarcopenia market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the digital therapeutics sarcopenia industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.